Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection [Phase 2]

View source ↗

Summary

A phase 2 trial evaluated ABT-333 alone and in combination with pegylated interferon and ribavirin for genotype 1 chronic hepatitis C virus infection, assessing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-333 (ABT-333)
• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-01-08